Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06378580
Status:
COMPLETED
Last Update Posted:
2024-04-22
First Post:
2024-04-17
Brief Title:
The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Sponsor:
Luo Cong
Organization:
Zhejiang Cancer Hospital
Study Overview
Official Title:
The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pancreatic ductal adenocarcinoma PDAC is a highly aggressive tumor with a poor prognosis despite the emergence of chemotherapies unmet medical needs and limited treatment options still exist for patients with metastatic PDAC mPDAC Surufatinib is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor VEGFR 1 2 3 fibroblast growth factor receptor 1 FGFR1 and colony stimulating factor 1 receptor CSF-1R and ex vivo experiments have demonstrated its effect on PC models
A retrospective analysis of patients with PDAC who underwent surufatinib at Zhejiang Cancer Hospital HangzhouChina from July 2022 to July 2023The database was extracted from the preoperative demographics blood markers and surgical pathology information of patients undergoing surufatinib in the investigators hospital
A retrospective analysis of patients with PDAC who underwent surufatinib at Zhejiang Cancer Hospital HangzhouChina from July 2022 to July 2023The database was extracted from the preoperative demographics blood markers and surgical pathology information of patients undergoing surufatinib in the investigators hospital
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LGF22H160084 | OTHER_GRANT | Zhejiang Provincial Basic Public Welfare Research Program | None |